Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
暂无分享,去创建一个
E. Vokes | P. Bycott | L. Rosen | E. Cohen | M. Kane | F. Worden | R. Cohen | M. Kies | E. Sherman | D. Shalinsky | Sinil Kim | M. Tortorici | A. Forastiere | Katherine F Liau | S. Kim
[1] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[2] John Smeraglia,et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.
[3] G. Demetri,et al. Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST , 2007 .
[4] D. Fraker,et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma , 2007 .
[5] L. Bastholt,et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC) , 2007 .
[6] J. Pasieka,et al. Anaplastic thyroid cancer and primary thyroid lymphoma: A review of these rare thyroid malignancies , 2006, Journal of surgical oncology.
[7] D. McDonald,et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.
[8] M. Schlumberger,et al. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Louise Davies,et al. Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.
[10] P. Angelos,et al. Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment. , 2006, Oncology.
[11] Betty Y. Y. Tam,et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.
[12] C. Kuo,et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. , 2006, American journal of physiology. Heart and circulatory physiology.
[13] J. Luk,et al. Increased Expression of Vascular Endothelial Growth Factor C in Papillary Thyroid Carcinoma Correlates with Cervical Lymph Node Metastases , 2005, Clinical Cancer Research.
[14] R. Herbst,et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[16] X-m Yu,et al. Increased expression of Vascular Endothelial Growth Factor-C in papillary thyroid carcinoma predicts cervical lymph node metastasis , 2005 .
[17] Gavin Thurston,et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.
[18] D. Grimm,et al. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. , 2004, Endocrinology.
[19] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[20] M. Saji,et al. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. , 2003, Annals of clinical and laboratory science.
[21] M. Cakir,et al. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[22] N. Sarlis. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research. , 2001, Current drug targets. Immune, endocrine and metabolic disorders.
[23] R. Tuttle,et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. , 2001, Surgery.
[24] L. Bresler*,et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. , 1999, The Journal of endocrinology.
[25] C. Key,et al. Prognostic factors for thyroid carcinoma , 1997, Cancer.
[26] G. Viglietto,et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. , 1995, Oncogene.
[27] F. Iida. Thyroid Carcinoma , 1991, Pediatrics In Review.
[28] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[29] D. Schoenfeld,et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma , 1985, Cancer.
[30] C. Hill,et al. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. , 1974, The New England journal of medicine.